NCT07139470View on ClinicalTrials.gov

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

April 15, 2027

Study Completion Date

October 15, 2027

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Sacituzumab Tirumotecan + anlotinib

"Phase I part: 3 prespecified doses (sac-TMT 4mg/kg Q2W +anlotinib 8mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib10mg Q3W, sac-TMT 4mg/kg Q2W +anlotinib12 mg Q3W).~Phase II part: sac-TMT patients Q2W +anlotinib RP2D Q3W."

Trial Locations (1)

300000

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER